Stock PPBT PURPLE BIOTECH LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Purple Biotech Ltd

Equities

PPBT

IL0007650166

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 07:54:38 26/06/2024 pm IST 		5-day change 1st Jan Change
19.4 ILa -1.02% Intraday chart for Purple Biotech Ltd -7.62% -39.18%
01/06 Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer CI
25/04 Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting CI

Valuation

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Capitalization 1 14.45 67.11 26.87 21.6 14.38 - -
Enterprise Value (EV) 1 14.45 67.11 26.87 21.6 14.38 14.38 14.38
P/E ratio -2.46 x - - - - - -
Yield - - - - - - -
Capitalization / Revenue - 67.1 x - - - - 1.87 x
EV / Revenue - 67.1 x - - - - 1.87 x
EV / EBITDA - - - - - - -
EV / FCF - - -16,03,194 x -10,83,998 x - - -
FCF Yield - - -0% -0% - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 19,561 1,72,106 1,84,277 2,44,589 2,75,548 - -
Reference price 2 0.7389 0.3899 0.1458 0.0883 0.0522 0.0522 0.0522
Announcement Date 11/02/20 02/03/21 08/02/23 05/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 1 - - - - - 7.7
EBITDA - - - - - - - -
EBIT 1 - -12.61 - -22.6 -22.27 -15.3 -19.45 -28.2
Operating Margin - -1,261.2% - - - - - -366.23%
Earnings before Tax (EBT) 1 - - -17.83 - - -12 -17 -
Net income 1 -5.85 -28 -18.38 - - -12 -17 -
Net margin - -2,799.9% - - - - - -
EPS -0.3000 - - - - - - -
Free Cash Flow - - - -16.76 -19.93 - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 11/02/20 02/03/21 09/02/22 08/02/23 05/03/24 - - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - -
EBITDA - - - - - - - - - - -
EBIT 1 - -5.081 -6.601 -5.122 -5.135 -5.747 -6.267 -4.466 -3.55 -3.35 -3.7
Operating Margin - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - -3 -2 -3
Net income -10.83 - - - - - - - -3 -2 -3
Net margin - - - - - - - - - - -
EPS -0.0600 - - - - - - - - - -
Dividend per Share - - - - - - - - - - -
Announcement Date 04/08/22 08/11/22 08/02/23 16/05/23 22/08/23 21/11/23 05/03/24 21/05/24 - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - -16.8 -19.9 - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - - 0.03 0 - - -
Capex / Sales - - - - - - - -
Announcement Date 11/02/20 02/03/21 09/02/22 08/02/23 05/03/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PURPLE BIOTECH LTD Stock Purple Biotech Ltd
-39.18% 14.44M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.43% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.57% 116B
ARGENX SE Stock argenx SE
+22.18% 27.03B
BIONTECH SE Stock BioNTech SE
-21.87% 20.36B
GENMAB A/S Stock Genmab A/S
-16.89% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.94% 15.91B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.6B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+61.95% 14.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.76% 13.59B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PPBT Stock
  4. Financials Purple Biotech Ltd